Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Scopus BioPharma Inc. (SCPS) had Return on Tangible Equity of 165.88% for the most recently reported fiscal year, ending 2022-12-31.
| Income Statement Financials | |
-- |
|
$-11.61M |
|
-- |
|
-- |
|
$11.71M |
|
$-11.71M |
|
-- |
|
$-11.71M |
|
$-11.71M |
|
$-11.71M |
|
$-11.71M |
|
$-11.71M |
|
$-11.71M |
|
$-11.71M |
|
$-11.71M |
|
21.09M |
|
21.09M |
|
$-0.55 |
|
$-0.55 |
|
| Balance Sheet Financials | |
$0.39M |
|
$0.00M |
|
$0.00M |
|
$0.39M |
|
$7.45M |
|
-- |
|
-- |
|
$7.45M |
|
$-7.06M |
|
$-7.06M |
|
$-7.06M |
|
21.09M |
|
| Cash Flow Statement Financials | |
$-8.13M |
|
$-0.00M |
|
$0.24M |
|
$7.94M |
|
$0.12M |
|
$-7.82M |
|
$0.35M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.05 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-8.13M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
165.88% |
|
|
Return on Tangible Equity |
165.88% |
-2986.47% |
|
165.88% |
|
$-0.33 |
|
$-0.39 |
|
$-0.39 |
|